Arthur F. Golden
Arthur F. Golden's purchase track record
How the stock did after each of Arthur F. Golden's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/21/2025 | TTRX | $93K | +6.7% | +56.9% | +13.2% |
| 10/23/2025 | TTRX | $100K | -4.4% | -32.3% | +5.5% |
| 11/8/2023 | EMR | $257K | +23.5% | +34.4% | +18.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Mizuho Maintains Outperform on Emerson Electric, Raises Target. Mizuho maintained its Outperform rating on Emerson Electric and raised its price target to $180, showing continued analyst support. This action reflects the broader bullish Wall Street sentiment surrounding the company. In the wider industrial sector, peer firms like Eaton and Dover are also drawing attention as market participants evaluate their respective positions.
Transaction History
| TTRX | ▼ Sell | Gift | 300,000 | $0 | 4/2/2026 | View on chart |
| TTRX | ▲ Buy | Open Market | 9,868 | $34K | 11/24/2025 | View on chart |
| TTRX | ▲ Buy | Open Market | 20,532 | $59K | 11/21/2025 | View on chart |
| TTRX | ▲ Buy | Open Market | 20,202 | $100K | 10/23/2025 | View on chart |
| TTRX | ▲ Buy | Grant | 10,000 | $0 | 10/8/2025 | View on chart |
| EMR | ▲ Buy | Open Market | 3,000 | $257K | 11/8/2023 | View on chart |
| EMR | ▲ Buy | Grant | 1,933 | — | 2/7/2023 | View on chart |
| EMR | ▲ Buy | Grant | 1,905 | — | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Capital initiates coverage on TTRX with $24 target
Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.
Lucid Capital initiates coverage on TTRX with $24 target. Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.